Posted inNews and Updates
Masitinib Shows Survival Benefits in ALS Clinical Trial
New trial data suggests the tyrosine kinase inhibitor masitinib may improve five-year survival rates in ALS patients by targeting neuroinflammation.
Posted inNews and Updates
FDA Clears XBiotech to Resume Rheumatology Clinical Trial
The FDA has lifted a clinical hold on XBiotech's trial for axial spondyloarthritis. Learn how this move impacts the future of rheumatology drug development.
Posted inNews and Updates
XBiotech Launches Phase II Trial for Axial Spondyloarthritis
XBiotech has launched a Phase II trial for Vilamakitug, a novel IL-1α inhibitor aimed at treating patients with active axial spondyloarthritis.
Posted inNews and Updates
First Patient Dosed in Breakthrough Huntington’s Stem Cell Trial
A groundbreaking clinical trial has begun testing neural stem cell therapy as a potential treatment to repair brain damage in Huntington’s disease patients.
Posted inNews and Updates
Novo Nordisk Confirms Data Breach: Clinical Trial Risks
Novo Nordisk reports a major data breach affecting clinical trial files. Learn about the security risks and the impact on patient data protection.
Posted inNews and Updates
Tafasitamab Combo Shows Promise in Phase III FrontMIND Trial
Explore new Phase III results for tafasitamab in treating DLBCL. Learn how this combination therapy aims to improve progression-free survival in patients.
Posted inNews and Updates
Jaypirca Combo Shows Promise in Phase III CLL Trial
New Phase III trial data shows promise for Jaypirca in combination therapy for patients with relapsed/refractory Chronic Lymphocytic Leukemia (CLL).
Posted inNews and Updates
FDA Approves Belzutifan-Pembrolizumab for Kidney Cancer
The FDA has approved the belzutifan-pembrolizumab combination to treat high-risk renal cell carcinoma. Learn how this dual therapy aims to prevent recurrence.
Posted inNews and Updates
Traws Pharma Faces Setback as UK Regulator Delays Flu Trial
Traws Pharma shares dip after the MHRA delays a key influenza clinical trial, demanding additional data. Learn about the impact on the drug pipeline.
Posted inNews and Updates
New PRMT5 Inhibitor IDE892 Enters Phase 1/2 Cancer Trials
IDEAYA Biosciences has launched a Phase 1/2 trial for IDE892, a targeted PRMT5 inhibitor for MTAP-deleted lung and pancreatic cancers. Learn the latest.